- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/10 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 261/10
Total number of patents in this class: 88
10-year publication summary
|
5
|
12
|
4
|
8
|
7
|
4
|
4
|
5
|
2
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Johns Hopkins University | 5675 |
6 |
| Cardioxyl Pharmaceuticals, Inc. | 49 |
6 |
| Blade Therapeutics, Inc. | 19 |
5 |
| Takeda Pharmaceutical Company Limited | 2708 |
4 |
| Gilead Sciences, Inc. | 2032 |
4 |
| The Board of Trustees of the University of Illinois | 2702 |
3 |
| Theravance Biopharma R&D IP, LLC | 456 |
3 |
| F. Hoffmann-La Roche AG | 7947 |
2 |
| Syngenta Participations AG | 1904 |
2 |
| Epizyme, Inc. | 373 |
2 |
| Nektar Therapeutics | 438 |
2 |
| Ikena Oncology, Inc. | 59 |
2 |
| Bristol-myers Squibb Company | 4880 |
1 |
| Hoffmann-La Roche Inc. | 3439 |
1 |
| E. I. du Pont de Nemours and Company | 4050 |
1 |
| AstraZeneca AB | 2892 |
1 |
| AstraZeneca UK Limited | 637 |
1 |
| Janssen Pharmaceutica N.V. | 3394 |
1 |
| Syngenta Crop Protection AG | 6074 |
1 |
| Abbott Laboratories | 2402 |
1 |
| Other owners | 39 |